Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
September 12 2024 - 9:34PM
UK Regulatory
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000
Public Offering of American Depositary Shares
BOSTON and LONDON, Sept. 12, 2024 (GLOBE
NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a
clinical-stage pharmaceutical company that aims to discover and
develop medicines that are transformational for patients, today
announced the pricing of an upsized underwritten public
offering of 15,254,237 of American Depositary Shares
(“ADSs”), each representing one ordinary share, at a price to the
public of $14.75 per ADS. The aggregate gross proceeds to Centessa
from this offering are expected to be approximately $225 million,
before deducting underwriting discounts and commissions and
offering expenses payable by Centessa. All ADSs sold in the
offering were offered by Centessa. The offering is expected to
close on or about September 16, 2024, subject to customary closing
conditions. Centessa has also granted the underwriters a 30-day
option to purchase up to an additional 2,288,135 ADSs at the
public offering price, less underwriting discounts and
commissions.
Goldman Sachs & Co. LLC, Leerink Partners,
Evercore ISI, Guggenheim Securities and BMO Capital Markets are
acting as joint book-running managers for the offering.
The ADSs are being offered pursuant to a
registration statement on Form S-3 that was filed with the
Securities and Exchange Commission (“SEC”) on September 11, 2024
and became automatically effective upon filing. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering have been filed, and a final prospectus supplement and
accompanying prospectus related to the offering will be filed, with
the SEC and are available on the SEC’s website located at
http://www.sec.gov. Copies of the final prospectus supplement and
the accompanying prospectus relating to the offering, when
available, may be obtained from: Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY
10282, telephone: (866) 471-2526, email:
prospectus-ny@ny.email.gs.com; Leerink Partners LLC, Syndicate
Department, 53 State Street, 40th Floor, Boston, MA 02109,
telephone: (800) 808-7525 ext. 6105, email: syndicate@leerink.com;
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 35th Floor, New York, NY 10055, telephone: (888)
474-0200, email: ecm.prospectus@evercore.com; Guggenheim
Securities, LLC, Attention: Equity Syndicate Department, 330
Madison Avenue, 8th Floor, New York, NY 10017,
telephone: (212) 518-9544, email:
GSEquityProspectusDelivery@guggenheimpartners.com; or BMO Capital
Markets Corp., Attention: Equity Syndicate Department, 151 W 42nd
Street, 32nd Floor, New York, NY 10036, email:
bmoprospectus@bmo.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Centessa
Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical
company that aims to discover and develop medicines that are
transformational for patients. Our most advanced programs include a
hemophilia program, an orexin agonist program for the treatment of
narcolepsy and other sleep-wake disorders, and an immuno-oncology
program focused on our LockBody® technology platform. We operate
with the conviction that each of our programs has the potential to
change the current treatment paradigm and establish a new standard
of care.
Forward Looking Statements
This press release contains forward-looking statements. Any such
statements in this press release that are not statements of
historical fact may be deemed to be forward-looking statements,
including those relating to Centessa’s expectations with respect to
the completion and timing of the public offering. Any
forward-looking statements in this press release are based on our
current expectations, estimates and projections only as of the date
of this release and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties related
to completion of the proposed public offering and the satisfaction
of customary closing conditions related to the public offering.
Risks concerning our programs and operations are described in
additional detail in our Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q, and our other reports, which are on file with
the U.S. Securities and Exchange Commission. We explicitly disclaim
any obligation to update any forward-looking statements except to
the extent required by law.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
Centessa Pharmaceuticals (LSE:0ACX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Centessa Pharmaceuticals (LSE:0ACX)
Historical Stock Chart
From Dec 2023 to Dec 2024